Richard L Schilsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9323739/publications.pdf Version: 2024-02-01

| 170 papers | 11,322 citations | 57758 44 h-index | 30087 103 g-index |
|---------------|---------------------|------------------------|-------------------------|
| 172 | 172 | 172 | 15185 |
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. JCO Oncology Practice, 2022, 18, e426-e441. | 2.9 | 16 |
| 2 | Patient Experiences, Trust, and Preferences for Health Data Sharing. JCO Oncology Practice, 2022, 18, e339-e350. | 2.9 | 2 |
| 3 | Use of Biosimilar Medications in Oncology. JCO Oncology Practice, 2022, 18, 177-186. | 2.9 | 15 |
| 4 | Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study Journal of Clinical Oncology, 2022, 40, 106-106. | 1.6 | 1 |
| 5 | Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with high tumor mutational burden (hTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study Journal of Clinical Oncology, 2022, 40, 107-107. | 1.6 | 5 |
| 6 | Cobimetinib plus vemurafenib (C+V) in patients (Pts) with solid tumors with BRAF V600E/d/k/R mutation: Results from the targeted agent and profiling utilization registry (TAPUR) study Journal of Clinical Oncology, 2022, 40, 3008-3008. | 1.6 | 7 |
| 7 | Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Journal of Clinical Oncology, 2022, 40, 3114-3114. | 1.6 | 2 |
| 8 | Governance of a Learning Health Care System for Oncology: Patient Recommendations. JCO Oncology Practice, 2021, 17, e479-e489. | 2.9 | 5 |
| 9 | American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care. Journal of Clinical Oncology, 2021, 39, 155-169. | 1.6 | 65 |
| 10 | The International Collaboration for Cancer Classification and Research. International Journal of Cancer, 2021, 148, 560-571. | 5.1 | 32 |
| 11 | Recommendations to Streamline and Standardize Clinical Trial Site Feasibility Assessments: An ASCO Research Statement. JCO Oncology Practice, 2021, 17, 41-51. | 2.9 | 3 |
| 12 | Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group. Clinical Cancer Research, 2021, 27, 2408-2415. | 7.0 | 14 |
| 13 | Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement. Clinical Cancer Research, 2021, 27, 2394-2399. | 7.0 | 47 |
| 14 | Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO- <i>Friends</i> Recommendations. Clinical Cancer Research, 2021, 27, 2430-2434. | 7.0 | 28 |
| 15 | Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer. Journal of Clinical Oncology, 2021, 39, 1165-1184. | 1.6 | 54 |
| 16 | Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. Npj Precision Oncology, 2021, 5, 33. | 5.4 | 5 |
| 17 | Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with <i>ERBB2 or ERBB3</i> amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study Journal of Clinical Oncology, 2021, 39, 5508-5508. | 1.6 | 9 |
| 18 | Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study Journal of Clinical Oncology, 2021, 39, 6043-6043. | 1.6 | 4 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with CDK4 amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study Journal of Clinical Oncology, 2021, 39, 11565-11565. | 1.6 | 6 |
| 20 | Mortality risk for patients undergoing cancer treatment who acquire SARS-CoV-2: ASCO registry Journal of Clinical Oncology, 2021, 39, 6509-6509. | 1.6 | 0 |
| 21 | What can heart failure trialists learn from oncology trialists?. European Heart Journal, 2021, 42, 2373-2383. | 2.2 | 9 |
| 22 | â€~Strategic' development of precision cancer medicine in the United States. Molecular Oncology, 2021, 15, 1747-1749. | 4.6 | 3 |
| 23 | Abstract CT173: Sunitinib (S) in patients (pts) with metastatic breast cancer (mBC) withFGFR1mutations or amplifications: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. , 2021, , . | | 2 |
| 24 | Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Journal of Clinical Oncology, 2021, 39, 2443-2451. | 1.6 | 97 |
| 25 | Talking the Talk About Tumor Genomic Testing. Journal of the National Cancer Institute, 2020, 112, 436-437. | 6.3 | 1 |
| 26 | Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist, 2020, 25, e405-e411. | 3.7 | 2 |
| 27 | Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies. Journal of Clinical Oncology, 2020, 38, 480-487. | 1.6 | 3 |
| 28 | Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. JCO Global Oncology, 2020, 6, 1461-1471. | 1.8 | 44 |
| 29 | Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology, 2020, 15, 743-750. | 3.6 | 25 |
| 30 | Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. JAMA Network Open, 2020, 3, e2014661. | 5.9 | 3 |
| 31 | Closing the Rural Cancer Care Gap: Three Institutional Approaches. JCO Oncology Practice, 2020, 16, 422-430. | 2.9 | 148 |
| 32 | Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Targeted Oncology, 2020, 15, 733-741. | 3.6 | 25 |
| 33 | Progress in Cancer Research, Prevention, and Care. New England Journal of Medicine, 2020, 383, 897-900. | 27.0 | 39 |
| 34 | The National Clinical Trials Network and the cooperative groups: The road not taken. Cancer, 2020, 126, 5008-5013. | 4.1 | 3 |
| 35 | Patient Preferences Regarding Informed Consent Models for Participation in a Learning Health Care System for Oncology. JCO Oncology Practice, 2020, 16, e977-e990. | 2.9 | 8 |
| 36 | Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO Oncology Practice, 2020, 16, 417-421. | 2.9 | 158 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Status Update on Data Required to Build a Learning Health System. Journal of Clinical Oncology, 2020, 38, 1602-1607. | 1.6 | 18 |
| 38 | Reply to M. Hutton-Potts and A.M. Joshua. JCO Oncology Practice, 2020, 16, 285-286. | 2.9 | 0 |
| 39 | Palbociclib in Patients With Non–Small-Cell Lung Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2020, 4, 757-766. | 3.0 | 52 |
| 40 | Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology, Journal of Clinical Oncology, 2020, 38, 1081. | 1.6 | 101 |
| 41 | Olaparib (O) in patients (pts) with pancreatic cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study Journal of Clinical Oncology, 2020, 38, 4637-4637. | 1.6 | 9 |
| 42 | Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with <i>BRAF V600E</i> mutations: Results from the TAPUR Study Journal of Clinical Oncology, 2020, 38, 122-122. | 1.6 | 10 |
| 43 | Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with <i>ERBB2</i> amplification or overexpression: Results from the TAPUR Study Journal of Clinical Oncology, 2020, 38, 132-132. | 1.6 | 38 |
| 44 | Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Journal of Clinical Oncology, 2020, 38, 133-133. | 1.6 | 28 |
| 45 | Olaparib (O) in patients (pts) with prostate cancer with BRCA1/2 inactivating mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study Journal of Clinical Oncology, 2020, 38, 5567-5567. | 1.6 | 2 |
| 46 | Biosimilar usage in practices within the ASCO PracticeNET learning network Journal of Clinical Oncology, 2020, 38, 77-77. | 1.6 | 2 |
| 47 | Determining If a Somatic Tumor Mutation Is Targetable and Options for Accessing Targeted Therapies. Journal of Oncology Practice, 2019, 15, 575-583. | 2.5 | 7 |
| 48 | Improving Cancer Diagnosis and Care: Patient Access to High-Quality Oncologic Pathology. Oncologist, 2019, 24, 1287-1290. | 3.7 | 11 |
| 49 | Effect of Public Deliberation on Patient Attitudes Regarding Consent and Data Use in a Learning Health Care System for Oncology. Journal of Clinical Oncology, 2019, 37, 3203-3211. | 1.6 | 20 |
| 50 | Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging Expertise. Journal of Clinical Oncology, 2019, 37, 1690-1694. | 1.6 | 12 |
| 51 | Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nature Medicine, 2019, 25, 751-758. | 30.7 | 362 |
| 52 | Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. Journal of Clinical Oncology, 2019, 37, 72-80. | 1.6 | 17 |
| 53 | Implementing Precision Medicine in Community-Based Oncology Programs: Three Models. Journal of Oncology Practice, 2019, 15, 325-329. | 2.5 | 54 |
| 54 | State of Cancer Care in America: Reflections on an Inaugural Year. Journal of Oncology Practice, 2019, 15, 163-165. | 2.5 | 2 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score. Journal of Clinical Oncology, 2019, 37, 336-349. | 1.6 | 101 |
| 56 | Challenges and approaches to implementing master/basket trials in oncology. Blood Advances, 2019, 3, 2237-2243. | 5.2 | 11 |
| 57 | Palbociclib in Patients With Pancreatic and Biliary Cancer With <i>CDKN2A</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2019, 3, 1-8. | 3.0 | 46 |
| 58 | Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation. JCO Precision Oncology, 2019, 3, 1-10. | 3.0 | 7 |
| 59 | Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Journal of Clinical Oncology, 2019, 37, 1014-1014. | 1.6 | 29 |
| 60 | Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study Journal of Clinical Oncology, 2019, 37, 9041-9041. | 1.6 | 7 |
| 61 | Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis Journal of Clinical Oncology, 2019, 37, LBA108-LBA108. | 1.6 | 10 |
| 62 | Hypertension and use of bevacizumab among patients treated in community settings Journal of Clinical Oncology, 2019, 37, e18279-e18279. | 1.6 | 0 |
| 63 | Use, attitudes, and perceptions of tumor genomic testing: Survey of TAPUR physicians Journal of Clinical Oncology, 2019, 37, 6531-6531. | 1.6 | 1 |
| 64 | Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Archives of Pathology and Laboratory Medicine, 2018, 142, 1242-1253. | 2.5 | 120 |
| 65 | Are Value Frameworks Missing the Mark When Considering Long-term Benefits From Immuno-oncology Drugs?. JAMA Oncology, 2018, 4, 333. | 7.1 | 10 |
| 66 | The evidence framework for precision cancer medicine. Nature Reviews Clinical Oncology, 2018, 15, 183-192. | 27.6 | 123 |
| 67 | Hans Christian Andersen and the Value of New Cancer Treatments. Journal of the National Cancer Institute, 2018, 110, 441-442. | 6.3 | 6 |
| 68 | Reply to S.D. Lucio. Journal of Clinical Oncology, 2018, 36, 2127-2127. | 1.6 | 0 |
| 69 | A New Look at the State of Cancer Care in America. Journal of Oncology Practice, 2018, 14, 397-399. | 2.5 | 3 |
| 70 | Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology, Journal of Clinical Oncology, 2018, 36, 1020-1044. | 1.6 | 108 |
| 71 | American Society of Clinical Oncology Statement: Biosimilars in Oncology. Journal of Clinical Oncology, 2018, 36, 1260-1265. | 1.6 | 88 |
| 72 | Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 2018, 2018, 1-14. | 3.0 | 98 |

| # | Article | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Streamlining Adverse Events Reporting in Oncology: An American Society of Clinical Oncology Research Statement. Journal of Clinical Oncology, 2018, 36, 617-623. | 1.6 | 18 |
| 74 | Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. Journal of Clinical Oncology, 2018, 36, 1631-1641. | 1.6 | 668 |
| 75 | The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census Survey. Journal of Oncology Practice, 2018, 14, e412-e420. | 2.5 | 114 |
| 76 | Accelerating anticancer drug development — opportunities and trade-offs. Nature Reviews Clinical Oncology, 2018, 15, 777-786. | 27.6 | 52 |
| 77 | Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. , 2018, 6, 108. | | 16 |
| 78 | Rationale, Opportunities, and Reality of Biosimilar Medications. New England Journal of Medicine, 2018, 378, 2036-2044. | 27.0 | 56 |
| 79 | Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 2018, 100, 35-45. | 2.8 | 29 |
| 80 | Access versus evidence: The regulators' dilemma. Clinical Trials, 2018, 15, 240-242. | 1.6 | 4 |
| 81 | Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with <i>CDKN2A</i> alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study Journal of Clinical Oncology, 2018, 36, 2532-2532. | 1.6 | 27 |
| 82 | Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE) Journal of Clinical Oncology, 2018, 36, 638-638. | 1.6 | 3 |
| 83 | Use of next-generation sequencing tests to guide cancer treatment: Results from a survey of U.S. oncologists Journal of Clinical Oncology, 2018, 36, 6529-6529. | 1.6 | 0 |
| 84 | Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1341-1367. | 1.6 | 318 |
| 85 | Reply to L. Casadaban et al. Journal of Clinical Oncology, 2017, 35, 1373-1374. | 1.6 | 0 |
| 86 | Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2392. | 7.4 | 670 |
| 87 | Core Clinical Data Elements for Cancer Genomic Repositories: A Multi-stakeholder Consensus. Cell, 2017, 171, 982-986. | 28.9 | 13 |
| 88 | Finding the Evidence in Real-World Evidence: Moving from Data to Information to Knowledge. Journal of the American College of Surgeons, 2017, 224, 1-7. | 0.5 | 39 |
| 89 | Reply to J.P. Jansen, A. Messori et al, and H.S.L. Jim et al. Journal of Clinical Oncology, 2017, 35, 1134-1134. | 1.6 | 0 |
| 90 | Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. Journal of Clinical Oncology, 2017, 35, 3737-3744. | 1.6 | 331 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Converging on the Value of Value Frameworks. Journal of Clinical Oncology, 2017, 35, 2732-2734. | 1.6 | 8 |
| 92 | Neutropenia related hospitalization risk in lung cancer patients with chemotherapy Journal of Clinical Oncology, 2017, 35, e18290-e18290. | 1.6 | 1 |
| 93 | Highlights from the 2016 WIN Symposium, 27–29 June 2016, Paris: personalised therapy beyond next-generation sequencing. Ecancermedicalscience, 2016, 10, 669. | 1.1 | 1 |
| 94 | Creating a Learning Health Care System in Oncology. , 2016, , 3-21. | | 4 |
| 95 | Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance). Journal of Clinical Oncology, 2016, 34, 3047-3053. | 1.6 | 51 |
| 96 | Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2016, 34, 3872-3879. | 1.6 | 28 |
| 97 | Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. Journal of Clinical Oncology, 2016, 34, 3992-3999. | 1.6 | 87 |
| 98 | Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received. Journal of Clinical Oncology, 2016, 34, 2925-2934. | 1.6 | 538 |
| 99 | Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology, Journal of Clinical Oncology, 2016, 34, 987-1011. | 1.6 | 141 |
| 100 | Response. Journal of the National Cancer Institute, 2016, 108, djw001. | 6.3 | 0 |
| 101 | Extended <i>RAS</i> Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. Journal of Clinical Oncology, 2016, 34, 179-185. | 1.6 | 225 |
| 102 | Impact of precision medicine in refractory malignancies: A meta-analysis of 13,203 patients in phase I clinical trials Journal of Clinical Oncology, 2016, 34, 11520-11520. | 1.6 | 4 |
| 103 | Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance) Journal of Clinical Oncology, 2016, 34, 3504-3504. | 1.6 | 249 |
| 104 | Highlights from the 2015 WIN Symposium: novel targets, innovative agents, and advanced technologies—a WINning strategy?. Ecancermedicalscience, 2015, 9, 564. | 1.1 | 2 |
| 105 | Using Big Data to Track Trends in Medical Practice. Journal of Oncology Practice, 2015, 11, 69-70. | 2.5 | 1 |
| 106 | Opportunities for Translational Epidemiology: The Important Role of Observational Studies to Advance Precision Oncology. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 484-489. | 2.5 | 13 |
| 107 | Moving from Evaluation to Value in Cancer Care. Clinical Cancer Research, 2015, 21, 947-949. | 7.0 | 4 |
| 108 | Integrating biomarkers in colorectal cancer trials in the West and China. Nature Reviews Clinical Oncology, 2015, 12, 553-560. | 27.6 | 11 |

| # | Article | IF | CITATIONS |
|-----|---|-------------------------------|--------------------------|
| 109 | Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors (Alliance) Tj ETQq1 🛛 | l 0.784314 rg 6 . 3 | gBŢ ₄ Overloc |
| 110 | Clinical Cancer Advances 2015: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2015, 33, 786-809. | 1.6 | 102 |
| 111 | Circadian variation in plasma 5-fluorouracil concentrations during a 24Âhour constant-rate infusion. BMC Cancer, 2015, 15, 69. | 2.6 | 22 |
| 112 | American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. Journal of Clinical Oncology, 2015, 33, 2563-2577. | 1.6 | 783 |
| 113 | Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection. Journal of the National Cancer Institute, 2015, 107, . | 6.3 | 20 |
| 114 | Innovative clinical trials for development of personalized cancer medicine. Molecular Oncology, 2015, 9, 933-934. | 4.6 | 4 |
| 115 | Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. Journal of the National Cancer Institute, 2015, 107, djv253. | 6.3 | 139 |
| 116 | Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. Journal of Clinical Oncology, 2015, 33, 3817-3825. | 1.6 | 393 |
| 117 | Modernizing Eligibility Criteria for Molecularly Driven Trials. Journal of Clinical Oncology, 2015, 33, 2815-2820. | 1.6 | 80 |
| 118 | A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget, 2015, 6, 14139-14152. | 1.8 | 22 |
| 119 | Personalized therapy in diverse cancers: Meta-analysis of 32,149 patients in phase II clinical trials Journal of Clinical Oncology, 2015, 33, 11097-11097. | 1.6 | 0 |
| 120 | Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405 Journal of Clinical Oncology, 2015, 33, 3585-3585. | 1.6 | 0 |
| 121 | Therapeutic Interventional Mapping System (TIMS): A novel strategy for the selection of tri-targeted therapy combinations for non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2015, 33, 7524-7524. | 1.6 | 0 |
| 122 | Precision Cancer Medicine: The Future Is Now, Only Better. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 61-69. | 3.8 | 38 |
| 123 | Reply to F.E. Vera-Badillo et al. Journal of Clinical Oncology, 2014, 32, 3198-3198. | 1.6 | Ο |
| 124 | Building a Rapid Learning Health Care System for Oncology: The Regulatory Framework of CancerLinQ. Journal of Clinical Oncology, 2014, 32, 2373-2379. | 1.6 | 97 |
| 125 | Reply to L.K. Griffeth et al and J.E. Battley et al. Journal of Clinical Oncology, 2014, 32, 2812-2813. | 1.6 | 0 |
| 126 | Implementing personalized cancer care. Nature Reviews Clinical Oncology, 2014, 11, 432-438. | 27.6 | 78 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncology, The, 2014, 15, e8-e21. | 10.7 | 413 |
| 128 | Wither the Cooperative Groups?. Journal of Clinical Oncology, 2014, 32, 251-254. | 1.6 | 8 |
| 129 | Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. Journal of Clinical Oncology, 2014, 32, 1521-1530. | 1.6 | 36 |
| 130 | American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. Journal of Clinical Oncology, 2014, 32, 1277-1280. | 1.6 | 354 |
| 131 | CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) lournal of Clinical Oncology, 2014, 32, LBA3-LBA3. | 1.6 | 68 |
| 132 | CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) Journal of Clinical Oncology, 2014, 32, LBA3-LBA3. | 1.6 | 178 |
| 133 | Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581 Journal of Clinical Oncology, 2014, 32, 455-455. | 1.6 | 4 |
| 134 | Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval Journal of Clinical Oncology, 2014, 32, 11047-11047. | 1.6 | 0 |
| 135 | ASCO's initiative to define value in cancer care. American Journal of Managed Care, 2014, 20, E1. | 1.1 | 0 |
| 136 | ecancermedicalscience. Ecancermedicalscience, 2013, 7, 344. | 1.1 | 0 |
| 137 | Publicly Funded Clinical Trials and the Future of Cancer Care. Oncologist, 2013, 18, 232-238. | 3.7 | 20 |
| 138 | Biologic Determinants of Tumor Recurrence in Stage II Colon Cancer: Validation Study of the 12-Gene Recurrence Score in Cancer and Leukemia Group B (CALGB) 9581. Journal of Clinical Oncology, 2013, 31, 1775-1781. | 1.6 | 163 |
| 139 | Developing a virtual collaborative to facilitate palliative care and quality improvement learning in oncology Journal of Clinical Oncology, 2013, 31, 252-252. | 1.6 | 1 |
| 140 | A genotype-directed study to optimize dosing of irinotecan according to the UGT1A1 genotype Journal of Clinical Oncology, 2013, 31, 2570-2570. | 1.6 | 0 |
| 141 | Lessons learned from the development of the CancerLinQ prototype: Clinical decision support Journal of Clinical Oncology, 2013, 31, 237-237. | 1.6 | 2 |
| 142 | Randomized Controlled Trials and Comparative Effectiveness Research. Journal of Clinical Oncology, 2012, 30, 4194-4201. | 1.6 | 32 |
| 143 | Development and Use of Integral Assays in Clinical Trials. Clinical Cancer Research, 2012, 18, 1540-1546. | 7.0 | 35 |
| 144 | Scarcity of vital oncology drugs: finding long-term solutions. Clinical Advances in Hematology and Oncology, 2012, 10, 597-9. | 0.3 | 0 |

| # | Article | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Targeted therapy for cancer: asking the right questions. Oncology, 2012, 26, 947-9. | 0.5 | Ο |
| 146 | Advanced clinical trials for China. Chinese Clinical Oncology, 2012, 1, 3. | 1.2 | 0 |
| 147 | Update in Hematology and Oncology: Evidence Published in 2010. Annals of Internal Medicine, 2011, 154, 487. | 3.9 | Ο |
| 148 | Accrual to Cancer Clinical Trials in the Era of Molecular Medicine. Science Translational Medicine, 2011, 3, 75cm9. | 12.4 | 18 |
| 149 | Drug approval challenges in the age of personalized cancer treatment. Personalized Medicine, 2011, 8, 633-640. | 1.5 | 4 |
| 150 | Commentary: Tackling the Challenges of Developing Targeted Therapies for Cancer. Oncologist, 2010, 15, 484-487. | 3.7 | 15 |
| 151 | Personalizing Cancer Care: American Society of Clinical Oncology Presidential Address 2009. Journal of Clinical Oncology, 2009, 27, 3725-3730. | 1.6 | 33 |
| 152 | How not to treat cancer. Lancet Oncology, The, 2008, 9, 504-505. | 10.7 | 3 |
| 153 | Phase I and II clinical trial design for targeted agents. Targeted Oncology, 2006, 1, 220-227. | 3.6 | 2 |
| 154 | A Concise History of the Cancer and Leukemia Group B: Fig. 1 Clinical Cancer Research, 2006, 12, 3553s-3555s. | 7.0 | 24 |
| 155 | Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of Cancer and Leukemia Group B. Journal of Clinical Oncology, 2006, 24, 4553-4557. | 1.6 | 73 |
| 156 | Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13. Journal of Clinical Oncology, 2005, 23, 2191-2200 | 1.6 | 98 |
| 157 | Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of Clinical Opcology, 2003, 21, 1431-1439 | 1.6 | 1,464 |
| 158 | Dose-Escalating Study of Capecitabine Plus Gemcitabine Combination Therapy in Patients With Advanced Cancer. Journal of Clinical Oncology, 2002, 20, 582-587. | 1.6 | 47 |
| 159 | End points in cancer clinical trials and the drug approval process. Clinical Cancer Research, 2002, 8, 935-8. | 7.0 | 18 |
| 160 | Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Investigational New Drugs, 1999, 17, 97-101. | 2.6 | 30 |
| 161 | Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemotherapy and Pharmacology, 1998, 42, 84-87. | 2.3 | 23 |
| 162 | Methotrexate: An Effective Agent for Treating Cancer and Building Careers. The Polyglutamate Era. Stem Cells, 1996, 14, 29-32. | 3.2 | 12 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 163 | Methotrexate: An Effective Agent for Treating Cancer and Building Careers. The Polyglutamate Era. Oncologist, 1996, 1, 244-247. | 3.7 | 5 |
| 164 | Prognostic factors for survival in patients treated in phase I clinical trials. Cancer, 1994, 74, 1965-1973. | 4.1 | 58 |
| 165 | Sequential therapy with dacarbazine and carmustine: a phase I study. Cancer Chemotherapy and Pharmacology, 1994, 34, 509-514. | 2.3 | 9 |
| 166 | Modulation of vinblastine resistance with cyclosporine: A phase I study. Clinical Pharmacology and Therapeutics, 1993, 54, 421-429. | 4.7 | 40 |
| 167 | Clinical cardiotoxicity of esorubicin (4?-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases. Investigational New Drugs, 1990, 8, 221-6. | 2.6 | 5 |
| 168 | Clinical Pharmacokinetics of High-Dose Leucovorin Calcium After Intravenous and Oral Administration. Journal of the National Cancer Institute, 1990, 82, 1411-1415. | 6.3 | 40 |
| 169 | A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer, 1989, 63, 30-36. | 4.1 | 42 |
| 170 | Concomitant Hydroxyurea, 5â€Fluorouracil, and Radiation Therapy for Recurrent Head and Neck Cancer: Early Results. Otolaryngology - Head and Neck Surgery, 1988, 98, 295-298. | 1.9 | 11 |